COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.18-2.09]recov. time9291Improvement, RR [CI]TreatmentControlRegeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Tau​2 = 0.00; I​2 = 0.0%Early treatment68%0.32 [0.20-0.52]19/2,80265/2,77368% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP94%0.06 [0.00-1.10]0/1868/22394% improvementRegeneron (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies59%0.41 [0.18-0.95]963/8,5801,103/8,69459% improvement6 casirivimab/imdevimab COVID-19 studiesc19regn.com 6/19/21Tau​2 = 0.58; I​2 = 80.8%; Z = 2.08 (p = 0.019)Lower RiskIncreased Risk
Casirivimab/imdevimab (REGN-COV2) is an artificial "antibody cocktail" designed to produce resistance to the SARS-CoV-2 coronavirus. It consists of a mixture of two monoclonal antibodies. The combination of antibodies is intended to prevent mutational escape. Submit updates/corrections below.
6/16
Late Horby et al., medRxiv, doi:10.1101/2021.06.15.21258542 (Peer Reviewed) death, ↓6.0%, p=0.17 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT 9,785 hospitalized patients in the UK showing lower mortality with casirivimab/imdevimab, with statistical significance reached for baseline seronegative patients.
5/21
Early Weinreich et al., medRxiv, doi:10.1101/2021.05.19.21257469 (Preprint) death, ↓67.0%, p=0.37 REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients
Details   RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629.
4/12
PEP Regeneron Press Release (Preprint) hosp./ER, ↓88.9%, p=0.06 Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (casirivimab and imdevimab)
Details   Press release for a phase 3 prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab.
3/23
Early Regeneron Press Release (Preprint) hosp./death, ↓71.3%, p<0.0001 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Details   Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor. Some variants may escape antibodies [1].
1/26
PrEP Regeneron Press Release (Preprint) symp. case, ↓93.6%, p=0.009 Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Details   Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/18..
9/29
Early Regeneron Press Release (Preprint) recov. time, ↓38.0%, p=0.22 Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Details   Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients..
8/21
In Vitro Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) in vitro Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Details   In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve..
8/21
N/A Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) animal study Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Details   Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit